Profile data is unavailable for this security.
About the company
Bliss GVS Pharma Limited is engaged in developing, manufacturing, and marketing pharmaceutical formulations. The Company’s product categories include pharma products, other healthcare products, and therapeutic index. Its pharma products include pharma products include capsules, creams, gels, ointments, dry powder for injection, effervescent tablets, eye/ear drops, nasal solution, lotions, lozenges, oral solids, and others. The Company’s other healthcare products include balm, nasal inhaler, solution, soap, roll on, shampoo, powder, spray, and petroleum jelly. Its brands include ANOMEX, ANOMEX DS, CONLAX 5/10, G - ALFENAC 100, GACET 80/125/170/250/500/1G, GMETH - 50/100, GSUNATE - 50/100/200, GVCAM - 7.5/15, GV-SOFT 1/2/3/4 G, LOFNAC - 12.5/25/50/100, MEFINOL, MELANEZ, MENINA - 25/100, TYRIDOL, VIGOTAMIN, COMIT 50, BG - CLIND, VAGID CL, ECOZOLE, GVGYL 500, GYNANFORT, GVGYL N, KLOVINAL, LONART, LONART FORTE, LONART Dispersible, FINMOL, GACET-500, NOVOGLIP-5, GVZOLE, and DOXYCYCLINE.
- Revenue in INR (TTM)8.00bn
- Net income in INR634.20m
- Incorporated1984
- Employees831.00
- LocationBliss GVS Pharma Ltd102Hyde Park,Sakivihar Road, Andheri-EastMUMBAI 400072IndiaIND
- Phone+91 2 242160000
- Fax+91 2 228563930
- Websitehttps://www.blissgvs.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nectar Lifesciences Ltd | 16.49bn | 61.44m | 8.45bn | 1.69k | 137.08 | -- | 12.62 | 0.5126 | 0.275 | 0.275 | 73.96 | -- | -- | -- | -- | 9,782,218.00 | -- | -0.2956 | -- | -0.541 | 29.64 | 16.49 | 0.3725 | -0.4053 | -- | 1.06 | -- | -- | 10.53 | -9.56 | 120.66 | -36.29 | -5.06 | -- |
| Bajaj Healthcare Ltd | 4.76bn | -133.27m | 11.38bn | 944.00 | -- | -- | 77.32 | 2.39 | -4.82 | -10.30 | 172.62 | -- | -- | -- | -- | 5,041,608.00 | -- | 7.67 | -- | 14.11 | 48.43 | 33.26 | -2.80 | 7.99 | -- | 1.74 | -- | 4.90 | -26.69 | 5.04 | -122.55 | -- | 15.08 | -- |
| Ngl Fine Chem Ltd | 3.58bn | 420.29m | 12.21bn | 390.00 | 29.06 | -- | 31.67 | 3.41 | 68.03 | 68.03 | 580.00 | -- | -- | -- | -- | 9,188,328.00 | -- | 15.06 | -- | 19.58 | 52.02 | 43.53 | 11.73 | 13.15 | -- | 26.59 | -- | 3.06 | 21.79 | 17.20 | 101.58 | 15.47 | 14.49 | 0.00 |
| Bliss GVS Pharma Ltd | 8.00bn | 634.20m | 13.01bn | 831.00 | 20.79 | 1.29 | 13.06 | 1.63 | 5.94 | 5.94 | 75.55 | 96.05 | 0.6454 | 3.10 | 1.98 | 9,628,987.00 | 5.80 | 6.46 | 7.04 | 8.22 | 50.26 | 43.91 | 8.99 | 9.92 | 3.74 | -- | 0.0825 | 7.92 | 2.48 | -3.03 | 6.49 | -9.42 | -8.33 | -12.94 |
| JG Chemicals Ltd | -100.00bn | -100.00bn | 13.44bn | 56.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -14.90 | -- | -43.84 | -- | -- | -- |
| Lincoln Pharmaceuticals Ltd | 5.92bn | 979.63m | 13.62bn | 1.70k | 13.90 | -- | 12.46 | 2.30 | 48.91 | 48.91 | 295.69 | -- | -- | -- | -- | 3,483,600.00 | -- | 13.95 | -- | 16.54 | 51.92 | 50.65 | 16.54 | 14.71 | -- | 60.93 | -- | 3.44 | 13.76 | 9.66 | 27.99 | 13.88 | 21.54 | 3.71 |
| Kopran Ltd | 6.37bn | 592.79m | 13.84bn | 358.00 | 19.77 | -- | 19.01 | 2.17 | 14.53 | 14.53 | 150.01 | -- | -- | -- | -- | 17,794,040.00 | -- | 8.47 | -- | 12.23 | 36.03 | 32.93 | 9.31 | 8.89 | -- | 27.17 | -- | 25.41 | 11.54 | 11.42 | 87.11 | 16.23 | 12.53 | -- |
| Jagsonpal Pharmaceuticals Ltd | 2.27bn | 243.00m | 14.37bn | 1.03k | 60.46 | 7.29 | 50.38 | 6.34 | 8.98 | 8.98 | 83.78 | 74.42 | 0.9703 | 5.13 | 9.92 | 2,213,181.00 | 10.39 | 10.95 | 12.40 | 13.29 | 58.16 | 58.13 | 10.71 | 9.21 | 2.60 | 32.84 | 0.0474 | 43.81 | -11.83 | 4.58 | -15.94 | 25.50 | -35.69 | 82.06 |
| Remus Pharmaceuticals Ltd | 2.12bn | 215.37m | 15.42bn | 48.00 | 70.08 | 17.75 | 57.37 | 7.26 | 37.34 | 37.34 | 374.91 | 147.42 | 1.46 | 7.61 | 3.56 | 44,270,750.00 | 17.80 | -- | 44.48 | -- | 22.67 | -- | 12.22 | -- | 1.12 | 55.56 | 0.0997 | -- | 371.94 | -- | 153.29 | -- | -- | -- |
| Zota Health Care Ltd | 1.98bn | -242.34m | 16.03bn | 445.00 | -- | -- | 3,431.57 | 8.09 | -9.27 | -9.27 | 76.32 | -- | -- | -- | -- | 4,452,605.00 | -- | -1.38 | -- | -1.85 | 49.86 | 35.95 | -12.23 | -1.33 | -- | -2.87 | -- | -- | 28.96 | 16.08 | -148.54 | -- | 39.85 | 0.00 |
| Sigachi Industries Ltd | 4.10bn | 594.65m | 16.44bn | 991.00 | 30.75 | -- | 23.11 | 4.01 | 1.60 | 1.60 | 10.97 | -- | -- | -- | -- | 4,136,886.00 | -- | 14.77 | -- | 19.57 | 52.33 | 50.30 | 14.43 | 14.92 | -- | 7.19 | -- | 1.61 | 32.08 | 25.34 | 31.34 | 24.64 | 70.35 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Life Insurance Corporation of India (Investment Portfolio)as of 30 Sep 2023 | 6.90m | 6.57% |
| Dimensional Fund Advisors LPas of 03 Oct 2024 | 376.82k | 0.36% |
| American Century Investment Management, Inc.as of 03 Oct 2024 | 32.76k | 0.03% |
| Dimensional Fund Advisors Ltd.as of 31 Aug 2024 | 23.93k | 0.02% |
| DFA Australia Ltd.as of 31 Aug 2024 | 2.56k | 0.00% |
| Acadian Asset Management LLCas of 30 Sep 2024 | 1.93k | 0.00% |
